Cargando…
Therapeutische Nanobodies gegen SARS-CoV-2
Monoclonal immunoglobulins are widely successful as therapeutics and have also been effective in treating COVID-19. However, their production in mammalian cells is expensive and cannot be scaled to meet the demand in a global pandemic. Camelid V(H)H antibodies (also called nanobodies), however, can...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Berlin Heidelberg
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8853039/ https://www.ncbi.nlm.nih.gov/pubmed/35194331 http://dx.doi.org/10.1007/s12268-022-1684-y |